Incorporación de los anticoagulantes de acción directa al arsenal terapéutico disponible: ¿progresa adecuadamente?

Caballero Requejo, Carmen; Urbieta Sanz, Elena; Iniesta Navalón, Carles; Gascón Cánovas, Juan José.
Aten. prim. (Barc., Ed. impr.) ; 51(3): 184-185, mar. 2019. graf
Artículo en Español | IBECS (España) | ID: ibc-182931

Documentos relacionados

  1. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis.
  2. In older patients with AF and frailty, switching from VKA to NOAC therapy increased a composite of major or CRNM bleeding at 12 mo.
  3. Computerized clinical decision support to improve stroke prevention therapy in primary care management of atrial fibrillation: a cluster randomized trial.
  4. Facility-Level Variation in Racial Disparities in Anticoagulation for Atrial Fibrillation: The REACH-AF Study.
  5. Early versus Later Anticoagulation for Stroke with Atrial Fibrillation.
  6. Direct Oral Anticoagulants in Chronic Liver Disease.
  7. Factor Xa Inhibitors versus warfarin in patients with morbid obesity and atrial fibrillation.
  8. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With Nonvalvular Atrial Fibrillation: Meta-Analysis.
  9. [Personalized approach for direct oral anticoagulant prescription: from theory to practice].
  10. CHA<sub>2</sub> DS<sub>2</sub> -VASc impact on risk following percutaneous coronary intervention in atrial fibrillation.